Actively Recruiting
A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate
Led by Peking University First Hospital · Updated on 2024-11-07
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Prostate-specific membrane antigen (PSMA) is a protein highly present on most prostate cancer cells and tumor blood vessels, making it an important target for cancer imaging. Researchers are evaluating a new PET imaging agent called [68Ga]P3, which specifically targets PSMA, to improve the diagnosis and study of cancers that show high PSMA expression. In this study, participants with suspected or confirmed prostate cancer will receive an intravenous injection of [68Ga]P3 at a dose between 0.06 and 0.08 mCi/kg. After injection, they will undergo PET/CT imaging to assess PSMA expression. This imaging technique is being studied for its ability to detect prostate cancer and evaluate its characteristics. Participants will be involved in PET/CT scans following the injection of [68Ga]P3. Researchers will evaluate the diagnostic and detection effectiveness of this imaging agent over one year. Additional assessments include measuring the radiation dose participants receive, quantitative analysis of the imaging agent, and correlating imaging findings with pathological results. The total study duration and follow-up are planned for one year.
CONDITIONS
Brief Title
68Ga-P3 PET/CT Imaging in Prostate
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed or suspected cancer
- Signed written informed consent
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single day
Participants receive an intravenous injection of 68Ga-P3 followed by PET/CT imaging to evaluate PSMA expression in the prostate.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
X
Xing Yang, Dr.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here